The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | G | Genito urinary system and sex hormones | |
| 2 | G04 | Urologicals | |
| 3 | G04B | Other urologicals, incl. antispasmodics | |
| 4 | G04BD | Urinary antispasmodics | |
| 5 | G04BD04 | Oxybutynin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 15 mg |
| T-DERMAL - Transdermal | 3.9 mg |
| Active Ingredient | Description | |
|---|---|---|
| Oxybutinin |
Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| KENTERA Transdermal patch | European Medicines Agency (EU) | MPI, EU: SmPC | |
| LYRINEL XL Prolonged release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| OXYTROL Transdermal system | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
